--- title: "Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of \"Buy\" by Brokerages" type: "News" locale: "en" url: "https://longbridge.com/en/news/285834702.md" description: "Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average \"Buy\" recommendation from thirteen analysts. One analyst rated it as a sell, while ten rated it as a buy and two as a strong buy. The average 1-year price target is $11.64. Recent reports show price target increases from Canaccord Genuity and Needham & Company. Insider Sukumar Nagendran sold 200,000 shares, reducing his stake by 14.97%. Institutional investors hold 77.70% of the stock. TSHA opened at $6.81, with a market cap of $1.96 billion and a 1-year price range of $2.06 to $7.30." datetime: "2026-05-10T08:33:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285834702.md) - [en](https://longbridge.com/en/news/285834702.md) - [zh-HK](https://longbridge.com/zh-HK/news/285834702.md) --- # Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by Brokerages Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $11.6364. Get **Taysha Gene Therapies** alerts: - Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" Several equities research analysts have issued reports on TSHA shares. Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, April 6th. Wall Street Zen cut shares of Taysha Gene Therapies from a "hold" rating to a "sell" rating in a research report on Saturday. Needham & Company LLC boosted their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, March 19th. Chardan Capital reissued a "buy" rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Finally, Truist Financial raised shares of Taysha Gene Therapies to a "strong-buy" rating in a research report on Wednesday, March 25th. **View Our Latest Stock Analysis on TSHA** ## Insider Buying and Selling at Taysha Gene Therapies - 3 Small-Cap Stocks For Your Fall Shopping List In other news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company's stock, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company's stock. ## Institutional Investors Weigh In On Taysha Gene Therapies Several hedge funds have recently modified their holdings of TSHA. Marex Group plc purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $40,000. Tower Research Capital LLC TRC lifted its position in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock worth $41,000 after purchasing an additional 10,742 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock worth $43,000 after purchasing an additional 4,607 shares during the period. Hedge funds and other institutional investors own 77.70% of the company's stock. ## Taysha Gene Therapies Price Performance Taysha Gene Therapies stock opened at $6.81 on Friday. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -17.92 and a beta of 1.25. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. Taysha Gene Therapies has a 1 year low of $2.06 and a 1 year high of $7.30. The firm has a 50-day moving average of $5.07 and a two-hundred day moving average of $4.93. Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, research analysts forecast that Taysha Gene Therapies will post -0.44 earnings per share for the current year. ## About Taysha Gene Therapies (Get Free Report) Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders. Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021. ## Further Reading - Five stocks we like better than Taysha Gene Therapies - Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due - Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches - Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money - Water Infrastructure: Why This Boring Sector Could Get Exciting _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Taysha Gene Therapies Right Now? Before you consider Taysha Gene Therapies, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list. While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [NGNE.US](https://longbridge.com/en/quote/NGNE.US.md) - [TFC.US](https://longbridge.com/en/quote/TFC.US.md) - [MRX.US](https://longbridge.com/en/quote/MRX.US.md) ## Related News & Research - [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | LIMN Stock News](https://longbridge.com/en/news/287218720.md) - [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)